I-Derm Pharma

Company Overview

Snapshot

Founded in January 2022 by Ofer Sarig and Eli Sprecher, I-Derm Pharma operates with 1–10 employees. The company has completed one funding round, attracting one investor, NGT HealthCare II, for its pre-seed capital.

Business overview

I-Derm Pharma is a Health Tech & Life Sciences company focused on developing a first-in-class oral therapy for moderate-to-severe psoriasis. The company's core technology involves a proprietary small-molecule family that targets an inflammatory pathway, demonstrating strong preclinical efficacy in chimeric mice with psoriatic human skin grafts and a favorable safety profile. I-Derm Pharma operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, serving the Healthcare & Life Sciences market.

Company Intelligence Q&A

When was I-Derm Pharma founded?

I-Derm Pharma was founded in January 2022.

Who are the founders of I-Derm Pharma?

The co-founders of I-Derm Pharma are Ofer Sarig, who serves as Co-founder & Scientific Advisor, and Eli Sprecher, who is Co-founder & Scientific and Clinical Advisor.

What is I-Derm Pharma's primary focus?

I-Derm Pharma is developing a first-in-class oral therapy for moderate-to-severe psoriasis, targeting inflammatory autoimmune skin diseases.

Which investor participated in I-Derm Pharma's funding round?

In January 2022, I-Derm Pharma received pre-seed funding from NGT HealthCare II.

What is the current product stage of I-Derm Pharma's therapy?

I-Derm Pharma's lead candidate is currently in the R&D stage, advancing toward an Investigational New Drug (IND) application.